Jetcraft First to Offer Microshield 360 Antimicrobial Treatment by F/LIST
20.7.2020 11:00:00 EEST | Business Wire | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is the launch customer for interiors specialist F/LIST’s Microshield 360 treatment program, which protects against SARS-CoV-2* and other pathogens that may otherwise live on cabin surfaces.
Additionally, Jetcraft is the first aircraft dealer using MicroShield 360. The coating system is available for all in-service aircraft purchased through the company, and will be applied to all eligible aircraft within Jetcraft’s owned inventory, beginning July 14.
Chad Anderson, president at Jetcraft, says: “MicroShield 360 is one of many ways we are expanding our offering to meet clients’ needs during Covid-19. We are pleased to be the first aircraft dealer implementing the treatment, so buyers can be confident their health is protected when purchasing directly from Jetcraft.
“Our first two jets, a Bombardier Challenger 604 and Global 5000, were treated by F/LIST on July 14. I was highly impressed by the speed of the application, which only took two hours from start to finish for a whole year of protection.”
MicroShield 360 is an antimicrobial coating system which is colorless, odorless and safe for all aircraft interiors. Owners can be reassured that it is eco-friendly, non-toxic and hypoallergenic, and won’t cause any deterioration to their aircraft cabin.
The interior application takes place in two parts: an initial disinfectant to sterilize the cabin, followed by the application of MicroShield 360, which forms a barrier of nanoscopic spikes. The spikes physically destroy germs by piercing the cell membranes, preventing them from adhering to and contaminating a surface.
An electrostatic sprayer is used to apply MicroShield 360, generating a molecular bond with the cabin surface which is equal to 40x the pull of gravity. As a result, the system is extremely abrasion resistant. Combined with regular cleaning, the treatment will ensure all surfaces are effectively self-disinfecting for 12+ months.
Sean Johnson, CEO, F/LIST Canada, adds: “In the present climate, it pays to be fastidious about your health and the cleanliness of your environment, particularly whilst traveling. With F/List partnering with Jetcraft we can bring MicroShield 360 directly to new aircraft owners, underlining how safe, controlled and comfortable travel can be when flying privately. F/List has long been known for innovative technologies that upgrade the cabin experience, and MicroShield 360 falls perfectly into that category.”
All Microshield 360 treatments are subject to Jetcraft approval. Some exclusions apply.
*SARS-CoV-2 is the virus that causes Covid-19.
ENDS
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
About F/LIST
F/LIST is a worldwide provider of interiors for business jets, yachts and residences, and engages more than 900 employees at eight locations in Europe, the Middle East and the Americas. Passion, reliability and a visionary spirit determine every step of this Austrian family-run business.
For more information, please visit https://f-list.at/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005038/en/
Contact information
8020 Communications.
Michaela Wilkins
Email: jetcraft@8020comms.com
Telephone: +44 (0)1483 447380
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release
Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 14:13:00 EEST | Press release
Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment across all three destinations reflects that conviction — we build for decades, and Oman is a country we intend to grow with in all circumstances.” — Naguib S. Sawiris, Chairm
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 14:00:00 EEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
